BG95739A - Means for the potentiation of the cyclophosphamide effect in intralesion application in solid malignant tumours - Google Patents

Means for the potentiation of the cyclophosphamide effect in intralesion application in solid malignant tumours

Info

Publication number
BG95739A
BG95739A BG95739A BG9573992A BG95739A BG 95739 A BG95739 A BG 95739A BG 95739 A BG95739 A BG 95739A BG 9573992 A BG9573992 A BG 9573992A BG 95739 A BG95739 A BG 95739A
Authority
BG
Bulgaria
Prior art keywords
intralesion
application
cyclophosphamide
potentiation
malignant tumours
Prior art date
Application number
BG95739A
Inventor
Vladi V Manev
Original Assignee
Manev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manev filed Critical Manev
Priority to BG95739A priority Critical patent/BG95739A/en
Publication of BG95739A publication Critical patent/BG95739A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The means is produced by simplified technology. It potentiates the effect of the intralesion application of cyclophosphamide in solid malignant tumours at manyfold decrease of the effective dose of cyclophosphamide both in single and in general whole-course dose. The means contains polyoxyethylene (20) sobritan trioleate from 20 to 40% solution in physiological solution from 100.0 to 400 g/l, 0.5-0.8% CaCl2.H2O solution, "Decaris" (Levamysol) 2.5-5 mg/l in physiological solution and indomethacine 2.5-5 mg/l in physiological solution.
BG95739A 1992-01-08 1992-01-08 Means for the potentiation of the cyclophosphamide effect in intralesion application in solid malignant tumours BG95739A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BG95739A BG95739A (en) 1992-01-08 1992-01-08 Means for the potentiation of the cyclophosphamide effect in intralesion application in solid malignant tumours

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG95739A BG95739A (en) 1992-01-08 1992-01-08 Means for the potentiation of the cyclophosphamide effect in intralesion application in solid malignant tumours

Publications (1)

Publication Number Publication Date
BG95739A true BG95739A (en) 1995-01-31

Family

ID=3924201

Family Applications (1)

Application Number Title Priority Date Filing Date
BG95739A BG95739A (en) 1992-01-08 1992-01-08 Means for the potentiation of the cyclophosphamide effect in intralesion application in solid malignant tumours

Country Status (1)

Country Link
BG (1) BG95739A (en)

Similar Documents

Publication Publication Date Title
AU3202595A (en) 1,2-substituted imidazolyl compounds for the treatment of inflammation
NZ513960A (en) Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
AU3142195A (en) Dermatological compositions containing benzoyl peroxide and a compound reducing skin irritation
DE69531457D1 (en) Sulfonamide
MX9603560A (en) Storage-stable prostaglandin compositions.
TR200000009T2 (en) Triazole compounds and their use as dopamine-D3-ligands.
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
YU60900A (en) Novel crystalline forms of an antiviral benzimidazole compound
SI0889886T1 (en) Novel phenanthridines substituted in the 6 position
CA2002859A1 (en) Method of treating epithelial disorders
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
FR2724844B1 (en) VITAMIN-CALCIUM THERAPEUTIC COMBINATION, PROCESS FOR OBTAINING SAME AND USE THEREOF
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
ES2055014T3 (en) PRODUCTS CONTAINING PSYLLIUM.
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
HK1050892A1 (en) Antitumor 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1- (substituted) hydrazines.
BG95739A (en) Means for the potentiation of the cyclophosphamide effect in intralesion application in solid malignant tumours
EP0831869A4 (en) Diphosphonate derivatives of therapeutic agents
AU2567097A (en) Novel vitamin d analogues
MX9500231A (en) 4-arylisoindole analgesics.
DE69127541D1 (en) PHARMACEUTICAL COMPOSITION
ES2170377T3 (en) COMPOSITION CONTAINING QUITOSANA.
HK1012238A1 (en) Use of benzimidazole anthelmintic in the treatment of microsporidial infections
ES2122005T3 (en) MEDICINAL PRODUCT CONTAINING (-) - METRIFONATE.